Charlotte Ellerton

Charlotte Ellerton

Auto-generated profile, based on publicly available information

Charlotte Ellerton

The Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, United Kingdom

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2021 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
PDF file
LALynne Aitkenhead
Lynne Aitkenhead
GKGauri Krishna
Gauri Krishna
CECharlotte Ellerton
Charlotte Ellerton
MOMoinuddin
Moinuddin
JMJessica Matcham
Jessica Matcham
EMElaine Murphy
Elaine Murphy

20 September 2023 in Clinical Nutrition
Verified
Journal Article
Open access
NLNicoline Løkken
Nicoline Løkken
MNMaja Risager Nielsen
Maja Risager Nielsen
MSMads Godtfeldt Stemmerik
Mads Godtfeldt Stemmerik
CECharlotte Ellerton
Charlotte Ellerton
KRKaroline Lolk Revsbech
Karoline Lolk Revsbech
JVJohn Vissing
John Vissing
McArdle disease is caused by myophosphorylase deficiency leading to blocked glycogenolysis in skeletal muscle. Consequently, individuals with McArdle disease have intolerance to physical activity, muscle fatigue, and pain. These symptoms vary according to the availability of alternative fuels for muscle contraction. In theory, a modified ketogenic diet (mKD) can provide alternative fuels in the form of ketone bodies and potentially boost fat oxidation. This randomized, single-blind, placebo-controlled, cross-over study aimed to investigate if a mKD improves exercise capacity in individuals with McArdle disease. Participants were randomized to follow a mKD (75-80% fat, 15% protein, 5-10% carbohydrates) or placebo diet (PD) first for three weeks, followed by a wash-out period, and then the opposite diet. The primary outcome was change in heart rate during constant-load cycling. Secondary outcomes included change in plasma metabolites, perceived exertion, indirect calorimetry measures, maximal exercise capacity, and patient-reported outcomes. Fifteen out of 20 patients with genetically verified McArdle disease completed all study visits, and 14 were included in the data analyses. We found that the mKD induced a metabolic shift towards increased fat oxidation (∼60% increase), and a 19-fold increase in plasma β-hydroxybutyrate (p < 0.05). The mKD did not improve heart rate responses during constant-load cycling but did improve patient-reported outcomes and maximal exercise capacity (∼20% increase) compared to the PD. The mKD did not alleviate all McArdle disease-related symptoms but did induce some positive changes. To date, no satisfactory treatment options exist other than exercise training. To that end, a mKD can be a possible nutritional strategy for some individuals with McArdle disease who are motivated to undertake a restrictive diet. clinical trials.gov: NCT04044508.